SCHEMBL23226754

SCHEMBL23226754

Cc1cc(C(=O)OCc2ccccc2)ccc1OCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.59
RXRA P19793 1/20 0.57
RXRB P28702 1/20 0.57
RXRG P48443 1/20 0.57
TDP1 Q9NUW8 2/20 0.57
KMT2A Q03164 2/20 0.57
SLC6A2 P23975 1/20 0.57
SLC6A3 Q01959 1/20 0.57
LMNA P02545 2/20 0.56
MRGPRX4 Q96LA9 6/20 0.54
MAPT P10636 3/20 0.54
ALDH1A1 P00352 2/20 0.54
HPGD P15428 2/20 0.54
RAB9A P51151 4/20 0.53
NPC1 O15118 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.50
SMPD1 P17405 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC8 Q9BY41 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13440181 0.93 FFAR4 (0.58) FFAR4RXRARXRBRXRGMRGPRX4
SCHEMBL25682702 0.89 TDP1 (0.57) TDP1KMT2ASLC6A2SLC6A3LMNA
SCHEMBL69503 0.89 RXRA (0.57) FFAR4RXRARXRBRXRGTDP1
SCHEMBL20059720 0.89 LMNA (0.59) FFAR4RXRARXRBRXRGTDP1
SCHEMBL27703866 0.87 FFAR4 (0.58) FFAR4RXRARXRBRXRGTDP1
SCHEMBL30141105 0.87 KMT2A (0.62) RXRATDP1KMT2ASLC6A2SLC6A3
SCHEMBL3960907 0.87 KMT2A (0.62) RXRATDP1KMT2ASLC6A2SLC6A3
SCHEMBL13440174 0.87 RXRA (0.70) FFAR4RXRARXRBRXRGMRGPRX4
SCHEMBL24851614 0.86 FFAR4 (0.51) FFAR4RXRARXRBRXRGMRGPRX4
SCHEMBL23362754 0.86 FFAR4 (0.51) FFAR4RXRARXRBRXRGMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637398-B2 Radiohalogen prosthetic moieties and radiolabeled biomolecules DUKE UNIVERSITY (US) 2026-05-26 US disclosed
US-20230002293-A1 RADIOHALOGEN PROSTHETIC MOIETIES AND RADIOLABELED BIOMOLECULES UNIV DUKE (US) 2023-01-05 US disclosed
US-20230002293-A1 RADIOHALOGEN PROSTHETIC MOIETIES AND RADIOLABELED BIOMOLECULES UNIV DUKE (US) 2023-01-05 US disclosed
EP-4058423-A1 RADIOHALOGEN PROSTHETIC MOIETIES AND RADIOLABELED BIOMOLECULES Duke University (US) 2022-09-21 EP disclosed
WO-2021096968-A1 RADIOHALOGEN PROSTHETIC MOIETIES AND RADIOLABELED BIOMOLECULES DUKE UNIVERSITY (US) 2021-05-20 WO disclosed
WO-2021068950-A1 AMIDE COMPOUND AND MEDICAL USE THEREOF AS STING INHIBITOR 中国药科大学 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002293-A1 RADIOHALOGEN PROSTHETIC MOIETIES AND RADIOLABELED BIOMOLECULES CD47, SHBG, KLK3 FFAR4 3269/4885RXRA 126/4885RXRB 123/4885
US-12637398-B2 Radiohalogen prosthetic moieties and radiolabeled biomolecules CD47, KLK3, SHBG FFAR4 3522/4885RXRA 203/4885RXRB 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.